Kornimate/medical-research-clean huggingface dataset:
omega-3 and vitamin e supplementation in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine whether simultaneous supplementation with omega-3 fatty acids and vitamin e is effective in the treatment of patients with rheumatoid arthritis.

the purpose of this study is to determine whether simultaneous supplementation with omega-3 fatty acids and vitamin e is effective in the treatment of patients with rheumatoid arthritis. most of studies on omega-3 fatty acids (omega-3) supplementation in patients with rheumatoid arthritis (ra) have clearly shown potentially beneficial changes in cytokine and eicosanoid metabolism. the overall clinical improvement, however, has been only moderate. one explanation is that an increased intake of omega-3 leads to a reduction in the availability of antioxidants and an increased generation of lipid peroxides. the majority of the anti-inflammatory drugs routinely used nowadays are cox (cyclo-oxygenase) inhibitors. mechanism of cox ii inhibitors is similar of omega-3. so, it is difficult to differentiate omega-3 net effects in some situations. existing clinical trials on omega-3 and vitamin e (vit e) are sometimes questioned due to using omega-6 fatty acids as placebo and neglecting omega-6 fatty acid intake in the diet. a comprehensive randomized controlled double-blind trial would have omega-6 fatty acids served as placebo in patients who are well matched in terms of therapies and drugs. comparison(s): comparison of groups supplemented with omega-3, omega-3 with vit e, and placebo (medium chain triglycerides: mct).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of rheumatoid arthritis according american college of rheumatology (acr) exclusion criteria: * infection * major joint malformations * simultaneous diseases like metabolic and gastrointestinal * being class iv according to acr * drug dose fluctuations * history of vit e and/or omega-3 supplements during past six months * gastric irrigations

Keywords: rheumatoid arthritis health related quality of life omega 3 fatty acids vitamin e
smart tnt for the conservative management of locally advanced rectal cancer

Conditions: Locally Advanced Rectal Cancer

Summary: the purpose of this research study is to find out how safe and effective is treating patients with locally advanced rectal cancer (larc) with chemotherapy first and then follow with radiation therapy to a higher dose than what is usually delivered and see if patients could have complete response and be spared from surgery.


Eligibility criteria:
inclusion criteria: 1. patients with newly diagnosed, biopsy proven, rectal adenocarcinoma. 2. primary tumor located ≤18 cm from margin verge. 3. primary tumor either a t3n0 or t1-4 n positive (as defined per pelvic mri; nodes ≤ 15 mm). 4. ≥ 18 years of age. 5. eastern cooperative oncology group (ecog) performance status 0-2. 6. serum liver function tests values within the range of 1.5 x upper limit of normal (within 6 weeks of enrollment). 7. negative pregnancy test for women of child-bearing potential (within 4 weeks of enrollment). 8. ability to understand and the willingness to sign a written informed consent document. 9. patient is assessed by a surgeon, medical oncologist and a radiation oncologist and deemed fit for total neoadjuvant chemotherapy (tnt) and surgery. exclusion criteria: 1. metastatic disease on initial work up (chest and abdomen contrast enhanced ct scan). 2. synchronous cancer found on colonoscopy. 3. previous history of pelvic radiotherapy. 4. history of concurrent, active malignancy other than non-metastatic skin cancer within the last 2 years. 5. symptomatic congestive heart failure of new york heart association class iii or iv, unstable angina pectoris or uncontrolled severe cardiac arrhythmia, myocardial infarction within the last 6 months. 6. psychiatric illness/social situations that would limit compliance with study requirements. 7. active (acute or chronic) or uncontrolled severe infections requiring intravenous antibiotics or active tuberculosis (tb). 8. patients with poorly controlled acquired immune deficiency syndrome (aids) who are not deemed candidates for folfox, mfolfirinox or capox chemotherapy. active connective tissue disorders, such as lupus or scleroderma, that, in the opinion of the treating physician may put the patient at high risk for radiation toxicity. 9. active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity 10. sensory or motor neuropathy ≥ grade 2. 11. women who are breast feeding. 12. exclusions due to mri use in study: ferromagnetic metal in body/eye, pacemaker, defibrillator, other mechanical device, or extreme claustrophobia (medication with anti-anxiety agents, such as ativan, may be attempted).
better evaluation of acute chest pain with computed tomography angiography

Conditions: Acute Coronary Syndrome; Acute Chest Pain

Summary: the purpose of this study is to determine whether cardiac ct can improve triage of acute chest pain patients in the emergency department.

myocardial infarction remains one of the most important causes of death and disability. therefore it is important that individuals with acute chest pain are accurately assessed without delaying appropriate treatment. acute coronary syndrome is only one cause for sudden chest pain, which is a very common complaint in the er. other life threatening causes such as pulmonary embolism and aortic dissection may also be the cause, although most chest discomfort has a benign reason (musculoskeletal, hyperventilation, oesophageal reflux, etc). the current work-up of suspected acute coronary syndrome, based on presentation, symptoms, ecg and biomarkers, is not efficient and results in unnecessary diagnostics and hospital admissions, as well as errors or delayed diagnoses, in a substantial number of patients. computed tomography angiography (cta) images atherosclerosis, coronary obstruction as well as myocardial hypoperfusion. we hypothesize that early use of cta is of incremental value and allows for accurate and immediate triage of patients with acute chest pain.

Eligibility criteria:
inclusion criteria: * acute chest pain or equivalent * patients older than 30 years * males \< 75 years and females \< 80 years exclusion criteria: * stemi * troponin \> 0.1 * history of known myocardial infarction, pci or cabg * pregnancy * contrast allergy * renal disfunction * no informed consent possible * no follow-up possible

Keywords: acute coronary syndrome
local injection of prp during repair of disrupted surgical wounds

Conditions: Role of Platelet Rich Plasma in Wound Healing

Summary: patients with disrupted wounds will either managed as usual or managed by platelet rich plasma local infiltration in the wound edges

the patients with disrupted surgical wounds will be cleansed, debrided and closed with infiltration of platelet rich plasma in one group and the other group will be closed without infiltration of platelet rich plasma

Eligibility criteria:
inclusion criteria: * disrupted surgical wounds after cesarean sections and other gynecological operations * body mass index 18-25 * hemoglobin \> 10.5gm/dl * albumin \>3.5gm/dl exclusion criteria: * medical disorders asdiabetes mellitus (dm), liver disease or systemic lupus erythymatosus (sle) * patient on corticosteriod therapy * thrombocytopenia * coagulation disorders

Keywords: platelet rich plasma disrupted wounds obstetrics and gynecology
performance of igras for tb infection diagnosis in elderly

Conditions: Ageing; Tuberculosis

Summary: background: diagnosis and screening for latent tuberculosis in old patients is of special interest in regards of the morbidity-mortality of this disease in that context. tb-infection diagnosis based on immunological memory detection can be impaired with age. new blood tests (qftb-g and t-spot.tb) specific for mtb infection have not been evaluated in those old patients.the primary endpoint of this study is the evaluation of the igras for active tb diagnosis in patients above 75 years old.

in vitro interferon gamma releasing assay (igra) are recommended for ltbi screening as or instead of tst, but there accuracy in those old patients are not known: as immune responses are impaired in elderly and some of them have already met m tuberculosis before active antibiotherapy exists.the aim of this study is to evaluate characteristics of the two commercials tests igra t-spot-tb® and quantiferon-tb-gold- in tube® and tst in old patients with or without active tuberculosis. principal outcome: - 3 tests performance for active tb diagnosis in patients older than 75 years-old secondary outcomes : * concordance between igras. * non-concordant results analysis * concordance of igras results with time of tb-infection * biobank methodology :diagnostic test performance study

Eligibility criteria:
inclusion criteria: * age \> 75 years * consent signed * hospitalized patient with start treatment of tuberculosis disease * french social right exclusion criteria: * tuberculosis disease treatment since 7 days * no 3 months follow-up possible * immunosuppression

Keywords: ageing tuberculosis interferon gamma releasing tests
effects of delta-9-thc and iomazenil in healthy humans

Conditions: Schizophrenia; Mental Disorders; Psychotic Disorders

Summary: the study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-thc or thc) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (eeg). thc is the active ingredient of marijuana, cannabis, "ganja", or "pot". iomazenil is a drug that works opposite to drugs like valium. the purpose of this study is to determine whether the administration of iomazenil will alter the effects of thc.


Eligibility criteria:
inclusion criteria: * exposed to cannabis at least once in their lifetime exclusion criteria: * cannabis naïve * history of hearing deficit

Keywords: schizophrenia mental disorders psychotic disorders schizophrenia and disorders with psychotic features cannabis
seroincidence study among men who have sex with men and transgender women - the imprep seroincidence study

Conditions: HIV Infections; Risk Reduction; Risk Behavior; Risky Health Behavior; STD; HIV Seropositivity; HIV Infection Primary

Summary: prep (pre-exposure prophylaxis) is an effective prevention strategy in which hiv-negative individuals take antiretroviral drugs (tenofovir disoproxil fumarate and emtricitabine - tdf/ftc) to reduce hiv acquisition. clinical studies have shown that the tdf/ftc combination protects msm and transgender women against hiv infection. according to the proud study, prep can decrease the risk of hiv infection among msm by 86% (90% ci 64-96). the international community recognizes that prep can be an additional tool in the framework of a combination prevention package for those most at risk of contracting hiv. data on hiv incidence among msm and trans women are largely unknown. in brazil, mexico and peru, data on the incidence of hiv among msm and trans women are very scarce, limited to small cross-sectional studies.current methods used to determine hiv-1 incidence have many limitations. these methods include mathematical modeling, retrospective calculations of aids case reports, age-based prevalence determinations, and prevalence determinations with multiple rounds of longitudinal surveys to estimate hiv incidence, which require numerous assumptions and inputs and can pose additional challenges in the era of expansion of antiretroviral therapy (art) and increased survival of hiv-1 infected individuals. on the other hand, prospective longitudinal cohort studies of high-risk individuals can be used to estimate incidence; however, they are often labor-intensive, complex, very expensive, difficult to implement in most countries, and have recruitment biases. laboratory methods can be unbiased and do not require complicated assumptions and case-by-case weighting. the cross-sectional use of recent hiv infection tests (tris) based on biomarkers offers, in principle, accessible, reliable and low risk of bias options for estimating incidence.


Eligibility criteria:
inclusion criteria: * msm and transgender women * aged 18 years or older * willingness and ability to sign an informed consent form. exclusion criteria: * individuals currently using prep, pep or receiving antiretroviral therapy; * individuals unable to understand the study or who do not agree to sign the consent form; * individuals who are participating in a clinical trial of antiretroviral medication or any investigational product to prevent the acquisition of hiv infection (for example, monoclonal antibodies such as pep or prep)

Keywords: msm tgw imprep hiv
phase i study to examine the effect of deferasirox on renal hemodynamics in β-thalassemia patients with transfusional iron overload

Conditions: β-thalassemia; Transfusional Iron Overload

Summary: the primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (gfr), renal plasma flow (rpf) and filtration fraction (ff).


Eligibility criteria:
inclusion criteria: * male or female patients ≥ 18 years of age without prior history of deferasirox treatment * β-thalassemia patients receiving regular transfusions every 2-5 weeks * transfusion history of ≥ 20 units of packed red blood cells exclusion criteria: * abnormal renal function at baseline * alt greater than 5 x uln at screening * patients with underlying cardiac disease requiring continuous iron chelation therapy other protocol-defined inclusion/exclusion criteria may apply.

Keywords: β-thalassemia transfusional iron overload renal function renal biomarkers deferasirox
outcome analysis of endoscopic resection of pituitary adenomas

Conditions: Pituitary Adenoma

Summary: the goal of this prospective study is to learn about the operative outcomes in patients with pituitary adenoma who receive endoscopic resection. the main question it aims to answer is: • what are the outcomes of patient following endoscopic resection? including visual, hormonal, survival, and functional outcomes. participants' data including clinical history, laboratory data, radiographic images, intraoperative videos will be evaluated and analyzed.


Eligibility criteria:
inclusion criteria: * adult patient * pathological diagnosis of pituitary adenoma * underwent endoscopic endonasal resection exclusion criteria: * age \ 80 years * non-pituitary adenoma pathologies * underwent non-endoscopic surgery

Keywords: pituitary adenoma
study of dalpiciclib combined with letrozole in the maintenance treatment of hr positive and her2 negative metastatic breast cancer after first-line chemotherapy

Conditions: Breast Cancer

Summary: this study aimed to evaluate the efficacy and safety of dalpiciclib combined with letrozole in the maintenance treatment of hr positive and her2 negative metastatic breast cancer after first-line chemotherapy.


Eligibility criteria:
inclusion criteria: 1. has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, her2 negative breast cancer. 2. age: 18 - 75 years old 3. eastern cooperative oncology group performance status (ecog ps)=0\~1 4. functions of liver and kidney is normal 5. agreed to take contraceptive measures during treatment exclusion criteria: 1. confirmed diagnosis of her2 positive disease. 2. central nervous system metastasis 3. patients who received prior treatment with any cdk4/6 inhibitor. 4. clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, congestive heart failure (new york heart association (nyha) class \> 2), or ventricular arrhythmia which need medical intervention； 5. researchers believe that is not suitable for the study
clinical trial to compare the safety and pharmacokinetics of yh22162 in healthy volunteers

Conditions: Hypertension

Summary: this is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to compare the safety and pharmacokinetics of yh22162 in healthy male volunteers. hypothesis: study drug and comparator drug are showing equal pharmacokinetics.

in arm1, 32 subjects will be assigned and the subjects will be administered "comparator drug" at day1/day43 and "study drug" at day22/64. in arm2, 32 subjects will be assigned and the subjects will be administered "study drug" at day1/day43 and "comparator drug" at day22/64.

Eligibility criteria:
inclusion criteria: * healthy male with body mass index(bmi) between 18.5 and 30 kg/m2 * who has not suffered from clinically significant disease * provision of signed written informed consent exclusion criteria: * history of and clinically significant disease * administration of other investigational products within 3 months prior to the first dosing * volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ecgs, or vital signs
mechanisms of pulmonary diffusion limitation in systemic sclerosis

Conditions: Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis

Summary: this study was designed to test the hypothesis that, irrespective of the degree of interstiai lung disease and/or pulmonary arterial hypertension, the combined measurement of lung diffusing capacity for nitric oxide and carbon monoxide, might be useful to provide a mechanistic interpretation of changes of diffusion subcomponents in systemic sclerosis (ssc).

in systemic sclerosis (ssc) the impairment of lung function is generally inferred from measurements of forced vital capacity (fvc) and standard lung diffusing capacity for carbon monoxide (dlco). however, fvc measurement does not provide an accurate estimate of lung restriction and dlco does not allow separate the alveolar membrane (dmco) from erythrocyte (deco) diffusive conductance for co. previous studies have shown that dmco and deco may change irrespective of overt intersitial lung disease (ild) and/or pulmonary arterial hypertension (pah). these changes may be consistent with a limitation of alveolar-capillary erythrocyte recruitment which impairs dm.this study was designed to test the hypothesis that, irrespective of the degree of ild and/or pah, combined dlno-dlco measurement might be useful to provide a mechanistic interpretation of dm and de changes in ssc.

Eligibility criteria:
inclusion criteria: * patients fulfilling the 2013 american college of rheumatology/european league against rheumatism criteria for a definite diagnosis of ssc with a total score ≥9 exclusion criteria: * unstable subjects and/or who have suffered from respiratory exacerbations in the previous 4-wk
msi-1256f (squalamine lactate) in combination with verteporfin in patients with "wet" age-related macular degeneration (amd)

Conditions: Macular Degeneration

Summary: age-related macular degeneration (amd) is a degenerative disease of the retina that causes a progressive loss of central vision. amd is the leading cause of legal blindness among adults age 50 or older in the western world. amd presents in two different types - "dry" and the more severe "wet" form. wet amd is caused by the growth of abnormal blood vessels in the macula. squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. this study will test the safety and efficacy of squalamine when administered with verteporfin therapy in patients with "wet" amd.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of "wet" age-related macular degeneration exclusion criteria: * prior treatment for "wet" age-related macular degeneration

Keywords: age-related macular degeneration - wet type
impact of the use of nandrolone on the treatment of malnutrition induced by cancer

Conditions: Cachexia; Cancer

Summary: compare the use of nandrolone associated with corticosteroid for the treatment of cancer-induced malnutrition to treatment with corticosteroids alone in patients with tumors in the high gastro-intestinal tract, liver, pancreas and bile ducts in palliative treatment.

* compare muscle mass values obtained before and after the use of anabolic steroids upon assessment by bioelectrical impedance analysis (bia). * compare the anabolic effect on quality of life (qlo) of the patient before and after the use of anabolic steroids. * compare data from laboratory tests such as complete blood count, albumin, c reactive protein and transferrin with drug intervention.

Eligibility criteria:
inclusion criteria: * cancer patients above 18 years old. * patients with tumors in the high gastro-intestinal, hepatobiliary and pancreatic tracts in palliation. * patients able to undergo bia. * malnourished patients as per the subjective global assessment produced by the patient (asg-ppp) and whose score is greater than nine. * patients who agree to participate in the study. exclusion criteria: * patients with malignant tumors of other metachronous or synchronous location except nonmelanoma skin tumor * patients with chronic renal failure. * patients on diuretics, recent or chronic. * patients on appetite stimulants and anabolic agents. * patients using pacemakers, which can interfere with the results of bia
the effect of premedication type(pharmalogical and non pharmalogical) on delirium

Conditions: Emergence Agitation

Summary: compare the effects of pharmacologic and nonpharmacologic premedications on postoperative emergence delirium and preoperative anxiety, vital parameters, blood pressure, heart rate, spo2, and pain at pacu 15 minutes after adenotonsillectomy .

compare the effects of 0.5 mg/kg oral midazolam, watching film "suko is being operated 'animation film (http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.wd-yhfu0piu) and playing a game named "fishing games" on postoperative emergency delirium by paed (post anestesic emergency delirium) scale at pacu at arrive and every 5 minutes for 15 minutes after adenotonsillectomy. investigators also evaluated "basic and 20 minutes after pharmacologic and nonpharmacolgic premedications on participitans anxiety by modified yale preoperative anxiety scale m-ypas scores" pain evaluated by flacc (behoviaral pain assesment scale),at arrive and every 5 minutes for 15 minutes after adenotonsillectomy. blood pressure(mmhg), heart rate(beat/min) and spo2(%) measured and recorded at arrive and every 5 minutes for 15 minutes after adenotonsillectomy.

Eligibility criteria:
inclusion criteria: * asa i-ii * pediatric patients * elective surgery * adenotonsillectomi exclusion criteria: * cronicdesease * mental retarde * hearing and visual impaired * prematurite

Keywords: premedication pediatric patients emergence agitation